Discovery of Selective SIRT2 Inhibitors as Therapeutic Agents in B-Cell Lymphoma and Other Malignancies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery of Selective SIRT2 Inhibitors as Therapeutic Agents in B-Cell Lymphoma and Other Malignancies
Authors
Keywords
-
Journal
MOLECULES
Volume 25, Issue 3, Pages 455
Publisher
MDPI AG
Online
2020-01-28
DOI
10.3390/molecules25030455
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Thienopyrimidinone Based Sirtuin-2 (SIRT2)-Selective Inhibitors Bind in the Ligand Induced Selectivity Pocket
- (2017) Sandeep Sundriyal et al. JOURNAL OF MEDICINAL CHEMISTRY
- A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity
- (2016) Hui Jing et al. CANCER CELL
- SIRT2 activates G6PD to enhance NADPH production and promote leukaemia cell proliferation
- (2016) Shuang-Nian Xu et al. Scientific Reports
- The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer
- (2016) Wenhui Zhou et al. Cell Reports
- Selective Sirt2 inhibition by ligand-induced rearrangement of the active site
- (2015) Tobias Rumpf et al. Nature Communications
- Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors
- (2014) Sumit S. Mahajan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Potent and Selective Sirtuin 2 (SIRT2) Inhibitors Using a Fragment-Based Approach
- (2014) Huaqing Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- SIRT2, une déacétylase aux multiples talents
- (2014) Salwa Sayd et al. M S-MEDECINE SCIENCES
- NAD+ and sirtuins in aging and disease
- (2014) Shin-ichiro Imai et al. TRENDS IN CELL BIOLOGY
- Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma
- (2013) J. E. Amengual et al. BLOOD
- SIRT1 and SIRT2: emerging targets in neurodegeneration
- (2013) Gizem Donmez et al. EMBO Molecular Medicine
- The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation
- (2013) L. Serrano et al. GENES & DEVELOPMENT
- SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling
- (2013) Juan Chen et al. HEPATOLOGY
- A Novel Sirtuin 2 (SIRT2) Inhibitor with p53-dependent Pro-apoptotic Activity in Non-small Cell Lung Cancer
- (2013) Gesine Hoffmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The 2.5 Å Crystal Structure of the SIRT1 Catalytic Domain Bound to Nicotinamide Adenine Dinucleotide (NAD+) and an Indole (EX527 Analogue) Reveals a Novel Mechanism of Histone Deacetylase Inhibition
- (2013) Xun Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS
- (2013) M. H. Yang et al. MOLECULAR CANCER RESEARCH
- SIRT1 and energy metabolism
- (2012) X. Li ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- The histone deacetylase SIRT2 stabilizes Myc oncoproteins
- (2012) P Y Liu et al. CELL DEATH AND DIFFERENTIATION
- SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis
- (2012) V Byles et al. ONCOGENE
- Prognostic significance of sirtuin 2 protein nuclear localization in glioma: An immunohistochemical study
- (2012) NATSUKO IMAOKA et al. ONCOLOGY REPORTS
- Sirtuin 1 and Sirtuin 3: Physiological Modulators of Metabolism
- (2012) Ruben Nogueiras et al. PHYSIOLOGICAL REVIEWS
- SIRT2 as a Therapeutic Target for Age-Related Disorders
- (2012) Rita Machado de Oliveira et al. Frontiers in Pharmacology
- SIRT2 activity is required for the survival of C6 glioma cells
- (2011) Xin He et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity
- (2011) Hyun-Seok Kim et al. CANCER CELL
- N1-Benzyl substituted cambinol analogues as isozyme selective inhibitors of the sirtuin family of protein deacetylases
- (2011) Federico Medda et al. MedChemComm
- SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis
- (2010) Yanze Li et al. GENES TO CELLS
- SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2
- (2010) Barrie Peck et al. MOLECULAR CANCER THERAPEUTICS
- SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis
- (2010) Ruth Luthi-Carter et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structure–Activity Studies on Splitomicin Derivatives as Sirtuin Inhibitors and Computational Prediction of Binding Mode
- (2008) Robert C. Neugebauer et al. JOURNAL OF MEDICINAL CHEMISTRY
- The SIRT2 Deacetylase Regulates Autoacetylation of p300
- (2008) Joshua C. Black et al. MOLECULAR CELL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started